US 5,326,756 AGranted

R-4-oxo-5 phosphononorvaline used as NMDA antagonists

AssigneeMerrell Dow Pharmaceuticals Inc.

InventorsJeffrey P. Whitten, Bruce M. Baron

Life of this patent

Estimating the term…

Abstract

The present invention is directed to a new class of beta-ketone, beta oxime and beta hydrazine phosphonate NMDA antagonists.

Claims6

Dependent claims

R-4-oxo-5-phosphononorvaline, a pharmaceutically acceptable acid addition salt thereof, a pharmaceutically acceptable basic addition salt thereof, or a tautomer thereof.

Dependencies are inferred from the claim text.

Facts

Application: 07/917,723Filed 20 Jul 1992 · continuation
Priority: 19 Sep 1989
Granted: 5 Jul 1994
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07F 9/653
Having nitrogen and oxygen atoms as the only ring hetero atoms: five-membered rings
C07F 9/3808
Not used, see subgroups: acyclic saturated acids which can have further substituents on alkyl
C07F 9/4006
The acid moiety containing a substituent or a structure which is considered as characteristic: esters of acyclic acids which can have further…
C07F 9/650952
Six-membered rings: having the nitrogen atoms in the positions 1 and 4

Family

Serial409,478Parent of this continuation-in-part · filed 19 Sep 1989
Serial508,333Parent of this continuation-in-part · filed 11 Apr 1990
Serial553,431Parent of this division · filed 20 Jul 1990
Serial790,291Parent of this continuation · filed 8 Nov 1991
US 5,095,009 AParent of this division
US 5,326,756 AThis patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results